Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer.
Gastric cancer
Preoperative wait time
Surgery
Survival
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
10
08
2018
accepted:
01
12
2018
pubmed:
12
12
2018
medline:
31
12
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Preoperative wait time is affected by various factors, and a certain time is needed before surgery. There is a concern that cancer treatment delay can lead to poor survival. The present study aimed to evaluate the impact of preoperative wait time on survival in patients with clinical stage (cStage) II/III gastric cancer. The study included patients with cStage II/III primary gastric cancer undergoing surgery between 2002 and 2012. Preoperative wait time was defined as the time from endoscopy for initial diagnosis to surgery. Patients were divided into the following three groups according to wait time: short wait group (≤ 30 days), intermediate wait group (> 30 and ≤ 60 days), and long wait group (> 60 and ≤ 90 days). Patient characteristics and survival were compared among the groups. This study included 467 male (67%) and 229 female (33%) patients, and the median patient age was 67 years. The numbers of cStage II and III patients were 332 (48%) and 364 (52%), respectively. The median wait time was 45 days. The body mass index was lower in the short wait group than in the other groups. A shorter wait time tended to be associated with a more advanced cStage. Although survival was significantly worse in the short wait group than in the long wait group, wait time was not identified as an independent prognostic factor in multivariate analysis. Preoperative wait time up to 90 days does not affect survival in patients with cStage II/III gastric cancer.
Sections du résumé
BACKGROUND
Preoperative wait time is affected by various factors, and a certain time is needed before surgery. There is a concern that cancer treatment delay can lead to poor survival. The present study aimed to evaluate the impact of preoperative wait time on survival in patients with clinical stage (cStage) II/III gastric cancer.
METHODS
The study included patients with cStage II/III primary gastric cancer undergoing surgery between 2002 and 2012. Preoperative wait time was defined as the time from endoscopy for initial diagnosis to surgery. Patients were divided into the following three groups according to wait time: short wait group (≤ 30 days), intermediate wait group (> 30 and ≤ 60 days), and long wait group (> 60 and ≤ 90 days). Patient characteristics and survival were compared among the groups.
RESULTS
This study included 467 male (67%) and 229 female (33%) patients, and the median patient age was 67 years. The numbers of cStage II and III patients were 332 (48%) and 364 (52%), respectively. The median wait time was 45 days. The body mass index was lower in the short wait group than in the other groups. A shorter wait time tended to be associated with a more advanced cStage. Although survival was significantly worse in the short wait group than in the long wait group, wait time was not identified as an independent prognostic factor in multivariate analysis.
CONCLUSION
Preoperative wait time up to 90 days does not affect survival in patients with cStage II/III gastric cancer.
Identifiants
pubmed: 30535877
doi: 10.1007/s10120-018-00910-y
pii: 10.1007/s10120-018-00910-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
864-872Références
Cancer Pract. 1999 May-Jun;7(3):130-5
pubmed: 10352075
Gastric Cancer. 2017 May;20(3):448-456
pubmed: 27586236
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
N Engl J Med. 2007 Nov 1;357(18):1810-20
pubmed: 17978289
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Surg Endosc. 2018 Jan;32(1):268-275
pubmed: 28664424
Arch Gynecol Obstet. 2012 Feb;285(2):493-7
pubmed: 21735188
Radiology. 2009 Nov;253(2):407-15
pubmed: 19789243
Qual Life Res. 2012 Nov;21(9):1519-25
pubmed: 22138966
Ann Surg. 2011 Apr;253(4):779-85
pubmed: 21475020
Obstet Gynecol. 2015 Feb;125(2):424-33
pubmed: 25569000
Ann Surg Oncol. 2013 Aug;20(8):2468-76
pubmed: 23529782
Int J Cancer. 2018 Sep 1;143(5):1093-1104
pubmed: 29603736
BJU Int. 2012 Jul;110(2):211-6
pubmed: 22093486
Surgery. 2013 Sep;154(3):421-8
pubmed: 23972647
BMJ. 2002 Jul 27;325(7357):196
pubmed: 12142308
BMC Cancer. 2018 Feb 6;18(1):151
pubmed: 29409475
JAMA Oncol. 2016 Mar;2(3):330-9
pubmed: 26659430
World J Surg. 2015 Nov;39(11):2742-7
pubmed: 26148519
Ann Surg Oncol. 2016 Aug;23(8):2679-89
pubmed: 27012988
J Thorac Oncol. 2011 Jul;6(7):1254-9
pubmed: 21610526
Br J Cancer. 2006 Oct 9;95(7):835-40
pubmed: 16969353
Ann Oncol. 2012 Oct;23(10):2731-7
pubmed: 22553194
BMJ. 1991 Aug 24;303(6800):437-40
pubmed: 1912834
BMC Cancer. 2017 Jan 3;17(1):2
pubmed: 28049452